ESR1 E380Q

CI-VAR-00000729Explore in graph →NP_000116.2:p.Glu380GlnNM_000125.3:c.1138G>CClinVar 376206 CIViC 1674

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm2
ESR1 D538G OR ESR1 Y537C OR ESR1 Y537N OR ESR1 Y537S OR ESR1 E380Q OR ESR1 Mutation	Lasofoxifene	Predictive	A	Supports Sensitivity Response	4	submitted	EID12934 In the randomized, open-label Phase II ELAINE-1 trial (n = 103), patients with ESR1‑mutated ER⁺/HER2⁻ mBC progressing after aromatase inhibitor plus CDK4/6 inhibitor therapy received either lasofoxife… (full text at CIViC) PMID 38072514 · Goetz et al., 2023 · Open in CIViC	civic
ESR1 E380Q	Palbociclib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4810 In a phase 3 clinical trial (NCT01942135) of 360 premenopausal and postmenopausal women with advanced, hormone receptor-positive breast cancer who had progressed during prior endocrine therapy, patien… (full text at CIViC) PMID 27269946 · Fribbens et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Estrogen Receptor-positive Breast Cancer1unmapped disease
ESR1 E380Q	Elacestrant	Predictive	A	Supports Sensitivity Response	2	submitted	EID12224 In the randomized, open-label, phase 3 EMERALD trial (NCT03778931), the selective ER-degrader (SERD) elacestrant was assessed in ER+/HER2- breast cancer patients who had previously been treated with e… (full text at CIViC) PMID 35584336 · Bidard et al., 2022 · Open in CIViC	civic